George Sledge, M.D.
Hoosier Cancer Research Network · Hoosier Oncology Group, Inc. · Hoosier Oncology Group, LLC
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name George Sledge, M.D. as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:53 UTC. Open this list on ClinicalTrials.gov
- N/ANCT01232881 · Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast CancerHoosier Cancer Research Network · terminated · Breast Cancer · study chair
- Ph2NCT00773474 · Lonafarnib in Metastatic Breast CancerGeorge Sledge · terminated · Metastatic Breast Cancer · principal investigator
- N/ANCT00537173 · Predicting Response and Toxicity in Patients Receiving Paclitaxel and Avastin for Breast CancerHoosier Cancer Research Network · terminated · Breast Cancer · principal investigator
- N/ANCT00235235 · A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast CancerHoosier Cancer Research Network · terminated · Breast Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:53 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in breast cancer.